No recommendation
No news or research item is a personal recommendation to deal. Hargreaves Lansdown may not share ShareCast's (powered by Digital Look) views.
(Sharecast News) - Drugmaker GSK said on Friday that its JAK inhibitor momelotinib has been granted orphan drug designation by both the US Food and Drug Administration and the European Medicines Agency for the treatment of VEXAS syndrome, a rare and severe autoinflammatory condition with no approved therapies.
GSK said the designations were supported by retrospective case studies suggesting JAK inhibitors may offer clinical benefit, as well as a case report indicating improvements in symptoms, inflammation and haematological markers with momelotinib.
The FTSE 100-listed company plans to evaluate the drug in VEXAS through its upcoming phase II/III ATLAS trial, which will support future global regulatory submissions. The trial forms part of a broader development programme assessing momelotinib across multiple haematological conditions.
Momelotinib, marketed as Ojjaara/Omjjara, has already been approved in the US for intermediate or highrisk myelofibrosis in adults with anaemia, and in the EU, UK and Japan for myelofibrosis with splenomegaly or diseaserelated symptoms in patients with moderate to severe anaemia.
As of 0815 BST, GSK shares were up 1.14% at 1,984.80p.
Reporting by Iain Gilbert at Sharecast.com
See latest RNS on Investegate
The value of investments can go down in value as well as up, so you could get back less than you invest. It is therefore important that you understand the risks and commitments. This website is not personal advice based on your circumstances. So you can make informed decisions for yourself we aim to provide you with the best information, best service and best prices. If you are unsure about the suitability of an investment please contact us for advice.